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ABSTRACT: 
Background: Between 2017 -2019 legislation was introduced in the UK that approved the 
home as a place for self-administration of misoprostol for early medical abortion. While 
research has shown that early medical abortion at home is as safe as in a clinical setting, 
women’s experiences in the UK in light of this change have not yet been investigated. This 
qualitative research explored the experiences of women in one region of Scotland, UK, who 
accessed early medical abortion with home self-administration of misoprostol. 
Methods: Qualitative interviews were conducted with 20 women who had recently 
undergone early medical abortion (≤ 69 days), with home self-administration of misoprostol. 
The data were analysed thematically using an approach informed by the Framework analytic 
approach.  
Results: Women appreciated the flexibility that home administration of misoprostol offered, 
including the opportunity to control the timing of the abortion. This was particularly 
important for women who sought not to disclose the abortion to others. Most women 
valued being in the comfort and privacy of the home when preparing for self-administration 
although a small number highlighted some concerns about being at home. Most women 
reported that self-administration of misoprostol was straightforward; some expressed 
concerns around assessing whether their experiences were ‘normal’.  
Conclusions: Women welcomed the opportunity for home self-administration of 
misoprostol. To further improve women’s early medical abortion experience we suggest 
that legislation be amended so that women can self-administer in an appropriate non-
clinical setting, not just their home. 
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Key Messages 
 Women welcomed the opportunity that self-administration of misoprostol at home gave 
them to control the timing of the abortion 
 Most women valued being in the comfort and privacy of the home when preparing for 
self-administration and passing the pregnancy  
 The home was a more challenging space for women who sought not to disclose the 
abortion to members of their household 
INTRODUCTION 
Research from a number of countries shows that early medical abortion with home self-
administration of misoprostol (hereafter EMAH-SaM) is safe [1] and that it is acceptable to 
women [2-5]. Between 2017 -2019, legislation was introduced in the UK that approved the 
home as a place for self-administration of misoprostol for early medical abortion (≤69 days 
gestation). While research has shown that early medical abortion at home is as safe as in a 
clinical setting [6], UK women’s experiences in the context of this change have not yet been 
investigated. This qualitative research explores the experiences of women choosing EMAH-
SaM, in one region of Scotland, UK. This is all the more significant in light of the temporary 
approval of home self-administration of both mifepristone and misoprostol for early 
medical abortion, implemented in response to COVID-19 [7, 8]. 
 
In Scotland, self-administration of misoprostol for early medical abortion was approved with 
effect from October 2017 [9]. Formerly, women who were eligible had to make at least two 
clinic visits; first to administer mifepristone; second, to have misoprostol tablets 
administered 24h to 72h later. Women then made an accompanied journey home with their 
misoprostol in situ. Research has identified the challenges some women faced having to 
return to the clinic to administer the misoprostol; the onset of pain and bleeding, and a 
small risk of passing the pregnancy while travelling home [2]; difficulties arranging child 
care; travelling long distances for those in more remote or rural areas [10]. To address these 
challenges, in NHS Lothian (National Health Service, Edinburgh and surrounding region),  
since December 2017 women have been permitted to take the mifepristone at the clinic 
then return to their home address with the misoprostol tablets and self-administer. Details 
of the treatment regimen in NHS Lothian are provided in Table 1. 
 
The aim of this study was to explore the experiences of women undergoing early medical 
abortion with home use of misoprostol in NHS Lothian in order to inform future service 
developments.  
Table 1: NHS Lothian Early Medical Abortion (with home self-administration of misoprostol) 
Qualification Criteria <9 +6 days gestation 
Supporting adult at home 
Location of Mifepristone 
Administration 
In clinic 
Dose of Mifepristone 200mg 
Location and Timing of 
Misoprostol 
Administration 
Self-administration at home at preferred time ideally 24-48 
hours after mifepristone, but up to 72 hours if earlier is not 
possible 
Dose of Misoprostol Initial dose of 4×200 μg tablets (800 μg misoprostol) 
  
Extra dose of 400 μg misoprostol provided with instructions 
that it should be taken if there was no or minimal bleeding 
within 4 hours of the initial dose 
Misoprostol 
administration method 
Vaginal or sublingual 
Support Telephone support provided by the clinic if required. Follow-
up calls are not routinely offered.  
 
METHODS 
This qualitative research is based on in-depth interviews with 20 women who had an early 
medical abortion with self-administration of misoprostol at home. 
 
Data collection 
Women attending a specialist abortion clinic in NHS Lothian, eligible for and selecting 
EMAH-SaM, were recruited between January and June 2019. At the end of the clinic visit, 
clinical staff informed women about the study (verbally and via an information pack) and 
those expressing an interest were asked to provide contact details. Of the 80 potential 
participants who agreed to be contacted by the researcher, 20 agreed to participate in an 
interview; 60 women did not respond to phone calls. Informed consent was obtained 
(written or verbal recording) prior to the interviews. Key characteristics of participants are 
outlined in Table 2. 
 
Interviews, lasting on average 60 minutes, were conducted 2-6 weeks following the abortion 
at the woman’s home, at the University of Edinburgh or by telephone, and were digitally 
recorded. Participants received a £15 voucher in recognition of their time. The topic guide 
(S1) focused on: reasons for choosing self-administration of misoprostol at home; women’s 
experiences of self-administration of misoprostol at home; interaction(s) with healthcare 
professionals; and views on abortion service developments.  
 
Table 2: Characteristics of EMAH-SaM Study Participants 
 Total  
(n=20) 
% of total 
Age (years)  
Mean 
Median 
Range 
 
28.2 
27 
21-45 
 
Highest Education Level Attained 
Secondary School 
Further Education (e.g. college) 
Higher education (i.e. university)  
Postgraduate  
 
6  
7 
5  
2  
 
30% 
35% 
25% 
10% 
Employment Status 
Employed (incl. self-employed) 
Student 
Unemployed/full-time parent 
 
15 
5  
0  
 
75% 
 25% 
 - 
Relationship Status (at interview) 
Single 
Cohabiting/married 
In relationship (not cohabiting) 
Separated  
 
4  
8  
8  
0  
 
20% 
40% 
40% 
 - 
Previous births 
Yes 
No 
 
7  
13  
 
35% 
65% 
Previous Termination of Pregnancy 
Yes 
No 
 
7  
13  
 
35% 
65% 
 
 
Data analysis 
A thematic analysis of the data, informed by the Framework approach, was conducted by 
the team (JH, NB and JA) [11, 12]. Following transcription, transcripts were subject to 
independent repeated reading and cross-comparison to identify recurrent themes, sub-
themes and issues (including those not foreseen at the study’s outset). A coding framework 
was developed which captured both the original research questions and emerging 
issues/themes. NVivo Qualitative Data Analysis software (QSR International) was used to 
facilitate data coding and retrieval. Coded datasets were then subject to further in-depth 
analysis to allow for the identification of additional themes and sub-themes.  
 
Ethical approval 
The study was reviewed and granted ethical approval by the Usher Research Ethics Group, 
University of Edinburgh (Application 1864; 14 January 2019). 
 
PATIENT AND PUBLIC INVOLVEMENT 
Patients were not directly involved in the design, recruitment for, and the conduct of, the 
interviews. A summary of the research findings was offered to all participants. 
 
RESULTS 
Women’s accounts of EMAH-SaM clustered around three core themes relating to the stages 
of the process: preparing to self-administer misoprostol; passing the pregnancy; being at 
home.  
 
Theme 1: Preparing to self-administer the misoprostol 
Women reported two key aspects that related to preparation: getting ready and choosing 
the right time.  
 
Getting ready 
The majority of the women reported choosing to go home immediately or soon after the 
clinic appointment in order to have “everything ready” (P07, 24). Preparations described by 
women included buying analgesics or other forms of pain relief such as hot water bottles; 
creating a comforting space; and buying and/or preparing comforting food. Women also 
spoke about trying to “relax” or “chill” and “mentally prepare for the next day, which we 
were told would be hectic” (P03, 28). 
Choosing the right time 
Several women noted the benefit of being able to control the timing of misoprostol 
administration, in contrast to having to administer in the clinic and then travel home.  
If I had taken it then [in the clinic] I would have had to arrange some sort of transport 
home… I don’t see how I could’ve travelled home in pain and then to start getting 
ready for the whole thing whilst already going through it. (P09, 19) 
Women reported following the advice given, administering the misoprostol 24 to 72 hours 
after taking the mifepristone in the clinic (see Table 3). The women described several 
benefits of being able to choose the time they self-administered the misoprostol, it enabled 
them: to make preparations (as above); to time the self-administration to fit with availability 
of their partner or a friend, to ensure they had support; to minimise the disruption to work. 
I do shift work and I was very concerned with… I still wanted to make sure I could do 
my shift (P12, 28) 
For around one third of the women, control over timing was valued because it enabled 
them to complete the abortion without disclosing to others, most commonly their children 
or other family members.  
I knew I had a limited amount of time before my husband and children came home … 
I managed to go to work and I managed to carry on doing everything I normally do 
and hide the fact that I was actually, yeah, having a termination. (P02, 36) 
A small number of women did not want to disclose the abortion to their employer so the 
choice of when to administer the misoprostol enabled them to complete the abortion and 
continue in their normal work pattern, thereby avoiding disclosure.  
Table 3: Method and timing of misoprostol self-administration 
Route of administration Timing of administration  
24 hours 48 hours  Over 48 hours  Total  
Vaginal  5 4 2 11 
Sublingual  6 3 0 9 
Total 11 7 2 20 
 
Theme 2: Passing the Pregnancy 
Getting it right: Self-administration of misoprostol 
Almost equal numbers of women opted for sublingual and vaginal routes of misoprostol 
self-administration (Table 3). Women reported choosing the sublingual method because it 
was possible to have the reassurance of a visible check that the pills were in place. In 
contrast, there were concerns raised about the pills ‘falling out’ of the vagina if not inserted 
‘high enough’. 
That’s why I put it in my mouth because in my mouth I can see everything, like, I 
knew exactly where everything was supposed to go. I think I wasn’t sure that in my 
vagina it would be put the right way. (P15, 29)  
However, most women who administered misoprostol vaginally reported it being 
straightforward and familiar given their experience using tampons.  
 
Gauging what is ‘normal’   
Women reported being very well informed by the clinic about the process. However some 
women, reported ‘panic’ and ‘fear’ about what was happening to them and difficulty being 
able to distinguish ‘normal’ symptoms from signs of ‘abnormal’ process in the absence of a 
healthcare professional.  
You don’t have a nurse with you so when you’re doing everything you’re like always 
questioning yourself ‘am I doing this right? (P13, 22) 
Almost half reported that they had phoned the abortion service for support, usually in the 
hours immediately following the misoprostol. Some of the calls related to administration of 
the misoprostol; a few women vomited not long after having administered the misoprostol 
sublingually and were concerned about whether it would still be as effective. Most calls 
were reported by the women as relating to their experience of pain and/or bleeding. 
 
Support from partner, family and friends 
Many of the women said that they had appreciated the support of those around them at 
home throughout the whole abortion process, offering company, cups of tea, or simply just 
‘being there’. Two women said that they had preferred to be left alone and were glad that 
the opportunity to take misoprostol at home allowed greater choice for women who did not 
want, or did not/could not have anyone there with them, despite this not being formally 
permitted.  
I think now that they give you the pills to take home you can sort of get away with 
not having a person with you, where before they wouldn’t give you the pills to go 
home, you had to get someone to go and collect you and pick you up from the clinic 
which is a lot more harder cause then you’ve got to explain to people what you’re 
going through (P16, 24) 
 
Theme 3: Being at Home 
Women described three important aspects to being at home - comfort, privacy, and control 
– which were enhanced by the change to misoprostol self-administration at home. 
 
Women often contrasted their home experience with what they thought (or in some cases 
had experienced) having the abortion in a ‘sterile’ hospital setting would have been like. The 
home was described as a private space and a source of comfort because it was a familiar 
rather than a strange space; filled with comforting objects; and occupied by family and 
friends.  
We fixed the living room into, like, a big massive cushion and just laid on this big 
massive couch bed” (P19, 24) 
I think it’s a big comfort to be in a place you know, in a place you are comfortable 
with and you don’t see strangers with their own disease and own issues and own 
lives. (P07, 24) 
Women also spoke of feeling more in control being at home. This related to being free to 
move around inside and outside the home; being able to control what they chose to do, for 
example watching TV; and being free to behave and to look however they wanted to (e.g. 
be impolite, be messy) without fear of judgement from others.  
I think knowing exactly where something is when I need it, like, if I want to lie on the 
floor I can,… I could ignore my partner…I didn’t have to respond cause I knew he 
would still understand the way partners do, as opposed to a medical professional 
saying 'what is your pain scale, how are you feeling, what can I do for you?  (P12, 28) 
Nevertheless, we cannot assume that the home is inherently an unproblematic space in 
which to self-administer abortion medication. Some women sought privacy from their 
family, either because of a sense of embarrassment around the visceral nature of abortion, 
or the desire not to disclose the abortion. Although not permitted under Scottish legislation 
[9], one participant reported booking into a hotel in an effort to conceal the abortion from 
members of her family. It was noticeable that the women who did not want to disclose the 
abortion, spoke less about comfort.  
I just done it, it wasn’t a case of me being comfortable.  I just made sure I had the 
things that I was going to need in the sense of, you know, sanitary towels and things 
like that. (P02, 36) 
 
DISCUSSION  
This qualitative study provided an in-depth understanding of the participants’ views on, and 
experiences of home self-administration of misoprostol, a research gap that was identified 
in a recent review [13]. Our analysis supports the existing evidence that home-self 
administration of misoprostol is acceptable to women and improves their overall 
satisfaction [2, 3, 14-19]. 
 
A key benefit of home self-administration of misoprostol is the control over timing that it 
offers women [2, 3, 20]. Our findings highlighted that by giving women the option to take 
the misoprostol at home, their ability to control the timing of the abortion and so to prepare 
for it, was enhanced. This was particularly important for those who had to manage childcare 
or work commitments, but also for women who sought not to disclose the abortion to 
family/household members or work colleagues. Given that the lack of control over timing(s) 
has been noted as a barrier to accessing abortion through formal healthcare, this change 
may improve access, in addition to improving women’s experience [4, 21, 22]. Nevertheless 
the women’s control over timing remained limited by having to attend the clinic to 
administer the mifepristone. In other contexts, home self-administration of both 
mifepristone and misoprostol has been demonstrated to be acceptable to women with no 
impact on efficacy or safety [23-25]. 
 
Our findings add weight to existing evidence that women value the comfort and privacy of 
passing their pregnancy in a home setting [2, 3, 14, 19] when compared to the more public, 
‘sterile’ space of the hospital. The opportunity to self-administer misoprostol at home not 
only limited women’s time in the clinic, but also enabled them to prepare the space of the 
home, thereby maximising their comfort. This raises the potential for the home to be 
considered a ‘therapeutic landscape’ – a place of healthcare provision, identified as 
producing health effects, and imbued with social, symbolic and experiential meaning [26, 
27].  
 
Nevertheless, we cannot assume that the home is inherently a positive therapeutic 
landscape for all women to undertake an abortion [27]. Reflecting research findings in 
countries with joint family living [28], some women choose not to disclose the abortion and 
for them the privacy afforded by the home is not simply being out of the gaze of strangers, 
but also being out of the gaze of family/members of their household. This also reinforces 
that moving abortion to the home does not remove the challenges that abortion stigma may 
pose for women [29, 30]. Indeed, the recommendation that another adult be present at 
home and the legal requirement that the abortion must take place at the women’s home 
address may be challenging for some women. We would suggest that legislation be 
amended so that women can administer in an appropriate non-clinical setting, not just their 
home, for example a friend’s, partner’s or parents’ home.  
 
The rich data generated has enabled further exploration of women’s experiences, and areas 
as yet unexplored in the literature. All women were recruited from one NHS Lothian clinic 
where 72% of women have EMAH-SaM and where, at the time of fieldwork, this had been 
an option for over a year [6]. The findings may not be reflective of women’s experiences 
where the service is newer. The study sample did not include women from rural and remote 
communities; further research is needed to explore the impact of EMAH-SaM for access to 
abortion services in areas where women may face particular challenges in accessing 
abortion services [10, 31]; and the acceptability to women of further policy change to 
enable them to administer both mifepristone and misoprostol at home, beyond the 
temporary provision in response to COVID-19. 
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